

## Instructions for Authors 2018

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

***Nomenclature and Abbreviations.*** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

***Clinical Trials.*** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

***Ethical Policies and Standards.*** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

***Submission of Manuscripts.*** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

***Galley Proofs.*** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2018** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases. T. MASUIISHI, H. TANIGUCHI, T. ETO, A. KOMORI, S. MITANI, H. HASEGAWA, Y. NARITA, M. ISHIHARA, T. TANAKA, S. KADOWAKI, T. URA, M. ANDO, M. TAJIKA, M. NOMURA, Y. SATO, H. MISHIMA, K. MURO ( <i>Nagoya; Tsuchiura; Kyoto; Nagakute, Japan</i> ) .....	6501
Comparison of Primary Tumor Size in Stage I and III Epithelial Ovarian Cancer. E. PETRU, C. HUBER, E. SAMPL, J. HAAS ( <i>Graz; Kirchdorf, Austria</i> ) .....	6507
Relationship Between Postoperative CRP and Prognosis in Thoracic Esophageal Squamous Cell Carcinoma. K. KATSURAHARA, A. SHIOZAKI, H. FUJIWARA, H. KONISHI, M. KUDOU, K. SHODA, T. ARITA, T. KOSUGA, R. MORIMURA, Y. MURAYAMA, Y. KURIU, H. IKOMA, T. KUBOTA, M. NAKANISHI, K. OKAMOTO, E. OTSUJI ( <i>Kyoto, Japan</i> ).....	6513
The Potential Use of a Ketogenic Diet in Pancreatobiliary Cancer Patients After Pancreatectomy. J.H. OK, H. LEE, H.-Y. CHUNG, S.H. LEE, E.J. CHOI, C.M. KANG, S.M. LEE ( <i>Seoul, Republic of Korea</i> ) .....	6519
Aggressive Cancer Behavior of Latent Gleason Pattern 5 in Prostatectomy Specimens. T. FUJIMURA, H. FUKUHARA, Y. YAMADA, S. TAGUCHI, T. SUGIHARA, A. NIIMI, M. NAKAMURA, T. NAKAGAWA, Y. IGAWA, Y. HOMMA, H. KUME ( <i>Tochigi; Tokyo, Japan</i> ) .....	6529
Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer. H. KAWAIDA, H. KONO, H. AMEMIYA, R. SAITOU, A. YAMAMOTO, N. HOSOMURA, M. WATANABE, A. KIMURA, S. FURUYA, H. SHIMIZU, H. AKAIKE, Y. KAWAGUCHI, M. SUDO, J. ITAKURA, H. HAYAKAWA, H. SHINDO, E. TAKAHASHI, S. TAKANO, M. FUKASAWA, S. ICHIKAWA, H. FUJII, D. ICHIKAWA ( <i>Yamanashi, Japan</i> ) .....	6537
Negative Impact of Coexisting Interstitial Lung Disease on Clinical Outcomes in Small-cell Lung Cancer Patients. K. AKAIKE, K. SARUWATARI, H. OKABAYASHI, S. HAMADA, Y. JODAI, T. JODAI, S. SAKATA, S. IYAMA, R. SATO, T. IRIKI, Y. TOMITA, S. SAEKI, H. ICHIYASU, K. FUJII ( <i>Kumamoto, Japan</i> ) .....	6543
HSP27, ALDH6A1 and Prohibitin Act as a Trio-biomarker to Predict Survival in Late Metastatic Prostate Cancer. S.Y. CHO, S. KANG, D.S. KIM, H.J. NA, Y.J. KIM, Y.D. CHOI, N.H. CHO ( <i>Goyang; Seoul; Pohang, Republic of Korea</i> ) .....	6551
Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia. J. LUCCHETTI, V. FORMICA, G. GIULIANO, D. COLETTA, L. GARGANO, D. MOROSETTI, P. SILERI, G. PALMIERI, M. ROSELLI ( <i>Rome, Italy</i> ) .....	6561
Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer. D. STEFANO, S. KOKKALI, E.-S. TRIPODAKI, M. DRIZOU, E. MAGOU, D. ZYLIS, M. PREVEZANO, M. KAPIRIS, D. NASI, A. NTOKOU, M. DEDE, A. ARDAVANIS ( <i>Athens, Greece</i> ) .....	6565
Risk Factors for Regional and Systemic Metastases in Patients with Sentinel Lymph Node-negative Melanoma. M. ERDMANN, D. SIGLER, U. USLU, J. GÖHL, R. GRÜTZMANN, G. SCHULER, V. SCHELLERER ( <i>Erlangen, Germany</i> ).....	6571
Patterns of Recurrence After Salvage Radiotherapy Encompassing Pelvic Lymphatics in Men with High-risk Prostate Cancer. M. KOH, Y.S. KIM, H. AHN, C.-S. KIM ( <i>Seoul, Republic of Korea</i> ) .....	6579
Book Reviews .....	6585
Errata .....	6589

Whole-brain Radiation Therapy for Breast Cancer Patients with Dural Metastasis Without Concomitant Brain Metastasis and Leptomeningeal Metastasis. M. SAKAGUCHI, T. MAEBAYASHI, T. AIZAWA, N. ISHIBASHI ( <i>Tokyo, Japan</i> ) .....	6405
Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry. M. BOEGEMANN, M. HUBBE, D. THOMAIDOU, S. BLACKBURN, N. BENT-ENNAKHIL, R. WOOD, D. BARGO ( <i>Muenster; Berlin, Germany; Athens, Greece; Bollington, UK; New York, NY, USA</i> ) ....	6413
Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel. M. INBAR, Y. HERISHANU, N. GOLDSCHMIDT, O. BAIREY, M. YUKLEA, L. SHVIDEL, R. FINEMAN, A. AVIV, R. RUCHLEMER, A. BRAESTER, D. NAJIB, O. ROUVIO, A. SHAULOV, U. GREENBAUM, A. POLLIACK, T. TADMOR ( <i>Haifa; Tel Aviv; Jerusalem; Petah-Tikva; Kfar-Saba; Rehovot; Afula; Naharia; Zefat; Beer-Sheva, Israel</i> ) .....	6423
The Issue of Survival After Colorectal Liver Metastasis Surgery: Parenchyma Sparing vs. Radicality. A. PALKOVICS, A. VERECZKEI, K.N. KALMÁR, A. FINCSUR, I. KISS, B. NÉMETH, A. PAPP ( <i>Pécs, Hungary</i> ) .....	6431
Atypical Femoral Fractures (AFF) from Bone Remodeling Agents in Patients with Cancer. M. KORDONI, G. RIGAKOS, Y.H. KIM, L. KAKLAMANIS, O. NIKOLATOU-GALITIS, L. HADJIYASSEMI, S. LABROPOULOS, E. RAZIS ( <i>Athens, Greece; Baltimore, MD, USA</i> ).....	6439
Novel Extracorporeal Hemoperfusion System for Hepatic Arterial Infusion of Cisplatin. S. SO, S. KOMATSU, A. TAKEBE, M. KIDO, M. TANAKA, H. TOYAMA, K. UENO, T. FUKUMOTO ( <i>Kobe, Japan</i> ) .....	6445
Salvage Carbon-ion Radiotherapy for Isolated Lymph Node Recurrence Following Curative Resection of Esophageal Cancer. Y. ISOZAKI, S. YASUDA, Y. AKUTSU, H. SHIMADA, S. OKAZUMI, Y. NABEYA, I. HOSHINO, K. MURAKAMI, D.K. EBNER, H. TSUJI, T. KAMADA, S. YAMADA, H. MATSUBARA ( <i>Chiba; Tokyo, Japan; Providence, RI, USA</i> ) .....	6453
Geo-location of Oncological Diseases in the Extra-urban Areas of Naples and Creation of Territorial Biobanks: An Important Tool to Study Potential Connections Between Environmental Factors and Cancer. M. CERRONE, M. CANTILE, O. SACCO, G. BOTTI ( <i>Naples, Italy</i> ) .....	6459
Impact of Osteopenia in Liver Cirrhosis: Special Reference to Standard Bone Mineral Density with Age. T. TOSHIMA, T. YOSHIKAZUMI, T. IKEGAMI, N. HARADA, S. ITOH, Y. MANO, T. MOTOMURA, Y. SOEJIMA, Y. MAEHARA ( <i>Fukuoka, Japan</i> ) .....	6465
Prognostic Significance of Conversion Surgery Following First- or Second-line Chemotherapy for Unresectable Gastric Cancer. M. FUKUCHI, E. MOCHIKI, T. ISHIGURO, Y. KUMAGAI, K. ISHIBASHI, H. ISHIDA ( <i>Kawagoe, Japan</i> ).....	6473
Plasma Catalase in Relation to Pain Following Midline Laparotomy: A Prospective Study of Patients with Benign Diseases and Patients with Cancer. I. SAIMANEN, J. KÄRKKÄINEN, T. SELANDER, M. PURDY, M. KOKKI, H. KOKKI, M. ESKELINEN ( <i>Kuopio, Finland</i> ) .....	6479
Primary Tumor Size Predicts Distant Metastasis of Mucosal Malignant Melanoma in Head and Neck. H. SUZUKI, G. TAKANO, N. HANAI, D. NISHIKAWA, Y. KOIDE, S. BEPPU, Y. HASEGAWA ( <i>Nagoya; Gifu, Japan</i> ) .....	6485
C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curative Resection for Pancreatic Cancer. Y. FUJIWARA, K. HARUKI, H. SHIBA, R. HAMURA, T. HORIUCHI, Y. SHIRAI, K. FURUKAWA, T. GOCHO, K. YANAGA ( <i>Tokyo, Japan</i> ) .....	6491

Deregulation of the SRC Family Tyrosine Kinases in Gastric Carcinogenesis in Non-human Primates. J.D.F. F.B. DA COSTA, C. DE CASTRO SANT' ANNA, J.A.P.C. MUNIZ, C.A.M. DA ROCHA, L.M. LAMARÃO, C.D.F.A.M. NUNES, P.P. DE ASSUMPCÃO, R.R. BURBANO ( <i>Belém; Ananindeua; Fortaleza, Brazil</i> ) .....	6317
The Contribution of Interleukin-12 Genetic Variations to Taiwanese Lung Cancer. M.-F. WU, Y.-C. WANG, H.-T. LI, W.-C. CHEN, C.-H. LIAO, T.-C. SHIH, W.-S. CHANG, C.-W. TSAI, T.-C. HSIA, D.-T. BAU ( <i>Taichung; Taoyuan; Taipei, Taiwan, ROC</i> ) .....	6321
<i>GLI1</i> and <i>CTNNB1</i> Knockdown Activates NOTCH and mTOR Signalling in NB4 Myeloid Leukaemia Cells. Y. OKUHASHI, M. ITOH, S. TOHDA ( <i>Tokyo, Japan</i> ).....	6329
Expression Pattern of <i>Cdkn2b</i> and Its Regulators in Canine Mammary Tumors. T.A.S. FARO, D.D.R. PINHEIRO, D.Q. CALCAGNO, W.L.A. PEREIRA, L.R.V.M. DE AGUIRRA, R.R. BURBANO, M.L. HARADA, B.D.N. BORGES ( <i>Belém, Brazil</i> ) .....	6333
Evodiamine Suppresses Survival, Proliferation, Migration and Epithelial–Mesenchymal Transition of Thyroid Carcinoma Cells. S.H. KIM, J.G. KANG, C.S. KIM, S.-H. IHM, M.G. CHOI, S.J. LEE ( <i>Chuncheon, Republic of Korea</i> ) .....	6339
<i>Clinical Studies</i>	
Combined Hepatic Resection and Radio-frequency Ablation for Patients with Colorectal Cancer Liver Metastasis: A Viable Option for Patients with a Large Number of Tumors. T. MASUDA, G.A. MARGONIS, N. ANDREATOS, J. WANG, S. WARNER, M.B. MIRZA, A. ANGELOU, C. DAMASKOS, N. GARMPIIS, K. SASAKI, J. HE, K. IMAI, Y.-I. YAMASHITA, C.L. WOLFGANG, H. BABA, M.J. WEISS ( <i>Baltimore, MD, USA; Kumamoto, Japan; Athens, Greece</i> ) .....	6353
Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer. E.I. HEATH, L.K. HEILBRUN, D. SMITH, W.M. SCHOPPERLE, Y. JU, S. BOLTON, Q. AHMED, W.A. SAKR ( <i>Detroit, MI; Boston, MA, USA</i> ) .....	6361
Improvement of Dysgeusia by Polaprezinc, a Zinc-L-carnosine, in Outpatients Receiving Cancer Chemotherapy. H. FUJII, C. HIROSE, M. ISHIHARA, H. IIHARA, H. IMAI, Y. TANAKA, N. MATSUHASHI, T. TAKAHASHI, K. YAMAGUCHI, K. YOSHIDA, A. SUZUKI ( <i>Gifu, Japan</i> ).....	6367
Underutilization of the CROSS Regimen Among US Radiation Oncologists: A National Survey of Practice Patterns. D.A. ELLIOTT, S.R. RANA, N. NABAVIZADEH, Y. CHEN, A. KUSANO, J.M. HOLLAND, T. MITIN ( <i>Toledo, OH; Portland, OR; Anchorage, AK, USA</i> ).....	6375
Radiofrequency Ablation vs. Cryoablation for Localized Hepatocellular Carcinoma: A Propensity-matched Population Study. J. XU, C. NODA, A. ERICKSON, M. MOKKARALA, R. CHARALEL, R. RAMASWAMY, Y. TAO, O. AKINWANDE ( <i>St. Louis, MO, USA</i> ) .....	6381
Cancer Patients in the Emergency Department: A “Nightmare” that Might Become a Virtuous Clinical Pathway. J.M. LEGRAMANTE, S. PELLICORI, A. MAGRINI, T. FRITTELLI, V. FORMICA, M. ROSELLI ( <i>Rome, Italy</i> ) .....	6387
Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha. K. MATTILA, P. RAANTA, V. LAHTELA, S. PYRHÖNEN, I. KOSKIVUO, P. VIHINEN ( <i>Turku, Finland</i> ) .....	6393
Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen. R. BENDARDAF, F.S. SHARIF-ASKARI, N.S. SHARIF-ASKARI, K. SYRJÄNEN, S. PYRHÖNEN ( <i>Sharjah, United Arab Emirates; Helsinki; Turku, Finland</i> ).....	6399

Chronic Sulforaphane Application Does Not Induce Resistance in Renal Cell Carcinoma Cells. J. RUTZ, E. JUENDEL, S. EULER, S. MAXEINER, S. JUSTIN, F. ROOS, F.K.-H. CHUN, R.A. BLAHETA ( <i>Frankfurt am Main; Mainz, Germany</i> ).....	6201
Suppression of Taxanes Cytotoxicity by Citrus Flavonoid Hesperetin in PPC-1 Human Prostate Cancer Cells. K. SAK, H. LUST, M. KASE, M. SAAR, J. JAAL ( <i>Tartu, Estonia</i> ) .....	6209
Oolong Tea Extract Induces DNA Damage and Cleavage and Inhibits Breast Cancer Cell Growth and Tumorigenesis. H. SHI, J. LIU, Y. TU, C.E. FRETER, C. HUANG ( <i>Quanzhou, PR China; Saint Louis, MO, USA</i> ) .....	6217
Dclk1 Inhibition Cancels 5-FU-induced Cell-cycle Arrest and Decreases Cell Survival in Colorectal Cancer. Y. SUEHIRO, Y. TAKEMOTO, A. NISHIMOTO, K. UENO, B. SHIRASAWA, T. TANAKA, N. KUGIMIYA, A. SUGA, E. HARADA, K. HAMANO ( <i>Ube, Japan</i> ) .....	6225
Piperlongumine Induces Apoptosis in Colorectal Cancer HCT 116 Cells Independent of Bax, p21 and p53 Status. F.D.S. MACHADO, F.M. MUNARI, F.J. SCARIOT, S. ECHEVERRIGARAY, C. AGUZZOLI, C. T. PICH, M.J. KATO, L. YAMAGUCHI, S. MOURA, J.A.P. HENRIQUES, M. ROESCH-ELY ( <i>Caxias do Sul, Brazil</i> ).....	6231
An Experimental Model of Breast Cancer Cells: Informative Protocol for <i>In Vitro</i> Culture. X. DU, K. KLASCHIK, P. MALLMANN, E. ISACHENKO, G. RAHIMI, Y. ZHAO, C. BRUNS, V. ISACHENKO ( <i>Cologne, Germany</i> ).....	6237
Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy. T. ENKHBAT, M. NISHI, K. YOSHIKAWA, H. JUN, T. TOKUNAGA, C. TAKASU, H. KASHIHARA, D. ISHIKAWA, M. TOMINAGA, M. SHIMADA ( <i>Tokushima, Japan</i> ) .....	6247
Coupling Dichloroacetate Treatment with Curcumin Significantly Enhances Anticancer Potential. P.-C. KAN, Y.-J. CHANG, C.-S. CHIEN, C.-Y. SU, H.-W. FANG ( <i>Taipei; Miaoli, Taiwan, ROC</i> ) .....	6253
The Antitumor Effects of Metformin on Gastric Cancer <i>In Vitro</i> and on Peritoneal Metastasis. N. SEKINO, M. KANO, Y. MATSUMOTO, H. SAKATA, K. MURAKAMI, T. TOYOZUMI, R. OTSUKA, M. YOKOYAMA, T. SHIRAIISHI, K. OKADA, T. KAMATA, T. RYUZAKI, H. MATSUBARA ( <i>Chiba, Japan</i> ) .....	6263
Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells. S. FU, J. LIN ( <i>Wuhan, PR China; Baltimore, MD, USA</i> ) .....	6271
Phoyunnanin E Induces Apoptosis of Non-small Cell Lung Cancer Cells via p53 Activation and Down-regulation of Survivin. P.P. PHIBOONCHAIYANAN, N. PETPIROON, B. SRITULARAK, P. CHANVORACHOTE ( <i>Pathumthani; Bangkok, Thailand</i> ) .....	6281
Atypical Protein Kinase C $\lambda/\iota$ Expression Is Associated with Malignancy of Oral Squamous Cell Carcinoma. J. BABA, M. KIOI, K. AKIMOTO, Y. NAGASHIMA, M. TAGURI, Y. INAYAMA, I. AOKI, S. OHNO, K. MITSUDO, I. TOHNAI ( <i>Yokohama; Noda; Tokyo, Japan</i> ) .....	6291
Hypoxia Stimulates the Epithelial-to-Mesenchymal Transition in Lung Cancer Cells Through Accumulation of Nuclear $\beta$ -Catenin. K.-H. LIU, Y.-T. TSAI, S.-Y. CHIN, W.-R. LEE, Y.-C. CHEN, S.-C. SHEN ( <i>New Taipei City; Taipei, Taiwan, ROC</i> ).....	6299
MicroRNA-107 Targets IKBKG and Sensitizes A549 Cells to Parthenolide. S. MOENG, H.A. SEO, C.Y. HWANG, G.A. CIPOLLA, D.J. LEE, H.J. KUH, J.K. PARK ( <i>Chuncheon; Seoul, Republic of Korea; Curitiba, Brazil</i> ).....	6309

7,8-Dihydroxy-3-aryl coumarin Induces Cell Death Through S-Phase Arrest in MDA-MB-231 Breast Cancer Cells. M.A. MUSA, V.L.D. BADISA, L.M. LATINWO, E. NTANTIE ( <i>Tallahassee, FL; Vancouver, WA, USA</i> ) .....	6091
BUBR1 Insufficiency Is Correlated with eNOS Reduction Experimentally <i>In Vitro</i> and <i>In Vivo</i> , and in Gastric Cancer Tissue. E. KAWAKUBO, T. MATSUMOTO, K. YOSHIYA, S. YAMASHITA, T. JOGO, H. SAEKI, E. OKI, T. FURUYAMA, Y. ODA, Y. MAEHARA ( <i>Fukuoka; Narita, Japan</i> ) .....	6099
CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells. K. KUHARA, K. TOKUDA, T. KITAGAWA, B. BARON, M. TOKUNAGA, K. HARADA, M. TERASAKI, O. UEHARA, T. OHTA, R. TAKAI, J.-I. HAMADA, M. KOBAYASHI, T. SHIMO, H. NAGAYASU, Y. KURAMITSU ( <i>Ishikari-Tobetsu; Ube, Japan; Msida, Malta</i> ) .....	6107
Modified Nucleosides – Molecular Markers Suitable for Small-volume Cancer? P. OPITZ, O. HERBARTH, A. SEIDEL, A. BOEHM, M. FISCHER, C. MOZET, A. DIETZ, G. WICHMANN ( <i>Leipzig, Germany</i> ) .....	6113
A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11. B. WANG, H. OGATA, Y. TAKISHIMA, S. MIYAMOTO, H. INOUE, M. KURODA, K. YAMADA, Y. HIJIKATA, M. MURAHASHI, H. SHIMIZU, T. OKAZAKI, Y. NAKANISHI, K. TANI ( <i>Fukuoka; Tokyo, Japan</i> ) .....	6121
IL-1 $\beta$ Induces Fascin Expression and Increases Cancer Invasion. M.K. LEE, J.H. PARK, S.H. GI, Y.S. HWANG ( <i>Seongnam, Republic of Korea</i> ) .....	6127
Colorectal Cancer Cell Line SW480 and SW620 Released Extravascular Vesicles: Focus on Hypoxia-induced Surface Proteome Changes. I. NAKURTE, K. JEKABSONS, R. REMBERGS, E. ZANDBERGA, A. ABOLS, A. LINĒ, R. MUCENIECE ( <i>Riga, Latvia</i> ) .....	6133
PROX1 Is Associated with Cancer Progression and Prognosis in Gastric Cancer. K. UETA, Y. OTOWA, Y. KAKEJI, M. HIRASHIMA ( <i>Kobe, Japan</i> ) .....	6139
TAK-733, a Selective MEK Inhibitor, Enhances Voreloxin-induced Apoptosis in Myeloid Leukemia Cells. E. JASEK-GAJDA, M. GAJDA, M. JASIŃSKA, J.A. LITWIN, G.J. LIS ( <i>Krakow, Poland</i> ) .....	6147
Lymphangiogenesis and Lymph Node Metastasis in Oral Squamous Cell Carcinoma. S. ARIMOTO, T. HASEGAWA, D. TAKEDA, I. SAITO, R. AMANO, M. AKASHI, T. KOMORI ( <i>Kobe, Japan</i> ) .....	6157
Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression. S. MIYOSHI, H. TSUGAWA, J. MATSUZAKI, K. HIRATA, H. MORI, H. SAYA, T. KANAI, H. SUZUKI ( <i>Tokyo, Japan</i> ) .....	6163
Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer. H.M. KIM, I. JEONG, H.J. KIM, S.K. KANG, W.S. KWON, T.S. KIM, K.H. PARK, M. JUNG, J. SOONG, S.-C. LIN, H.C. CHUNG, S.Y. RHA ( <i>Seoul, Republic of Korea; San Diego, CA, USA; New Taipei City, Taiwan, ROC</i> ) .....	6171
Benzoxazole-based Zn(II) and Cu(II) Complexes Overcome Multidrug-resistance in Cancer. G. SPENGLER, A. KINCSES, B. RÁCZ, B. VARGA, G. WATANABE, R. SAIJO, H. SEKIYA, E. TAMAI, J. MAKI, J. MOLNÁR, M. KAWASE ( <i>Szeged, Hungary; Matsuyama, Japan</i> ) .....	6181
Predicting Cytotoxicity of 2-Phenylindole Derivatives Against Breast Cancer Cells Using Index of Ideality of Correlation. A.A. TOROPOV, A.P. TOROPOVA ( <i>Milan, Italy</i> ) .....	6189
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells. C. SEMAAN, K.A. NEILSON, B. BROWN, M.P. MOLLOY ( <i>Sydney, Australia</i> ) .....	6195